Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

ASTRO: New Therapy Delays Progression of Recurrent Prostate Cancer

Findings from the trial, presented today at the 2025 American Society for Radiation Oncology Annual Meeting in San Francisco, showed that men who received the radioligand drug went a median of 17.6 months without disease progression, compared with 7.4 months for those who received SBRT alone.

September 28, 2025


September 28 2025

September 27 2025

September 26 2025

September 25 2025

September 24 2025

September 23 2025

September 22 2025

September 21 2025

September 20 2025

September 19 2025

September 18 2025

September 17 2025

September 16 2025

September 15 2025